Dose adjustments for baricitinib should be based on eGFR, not creatinine clearance. eGFR is universally reported, aligns with other major clinical trials, and this approach has been approved by the MHRA.
Dose adjustments for baricitinib should be based on eGFR, not creatinine clearance. eGFR is universally reported, aligns with other major clinical trials, and this approach has been approved by the MHRA.
Fill in the form and send the confirmation email to
pantheruk@imperial.ac.uk
Fill in the form and send the confirmation email to
pantheruk@imperial.ac.uk
Fill in the form and send the confirmation email to
pantheruk@imperial.ac.uk